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Abstract  Essential  thrombocythaemia  is  a  rare  pathology  in  adults  and  extremely  rare  in
children, making  it  a  diagnostic  challenge  for  paediatricians.  The  challenge  is  greater  when
patients are  asymptomatic,  despite  an  incidental  discovery  of  thrombocytosis.
We report  the  case  of  extreme  thrombocytosis  found  in  an  asymptomatic  child  of  3  years
with no  personal  history  or  familial  history.  Study  protocol  started  by  ruling  out  laboratory
errors, infectious  disease,  haemolytic  anaemia,  iron  deﬁciency  anaemia  and  autoimmune  dis-
eases. Bone  marrow  sample  conﬁrmed  elevated  megakaryocyte  production,  with  other  cell  lines
within normal  ranges.  Genetic  analysis  (including  JAK2  mutation)  was  also  negative,  leading  to
a differential  diagnosis  of  essential  thrombocythaemia.  Hydroxyurea  (10  mg/kg)  and  aspirin
(5 mg/kg)  were  prescribed.  A  moderate  reduction  in  platelet  count  was  achieved  after  4  weeks
of treatment.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Published  by  Masson  Doyma  México
S.A. All  rights  reserved.
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Trombocitemia  esencial  en  un  nin˜o  de  3  an˜os
Resumen  La  trombocitemia  esencial  es  poco  frecuente  en  adultos  y  extremadamente  rara
en población  pediátrica,  convirtiéndose  en  un  reto  diagnóstico  para  los  pediatras.  El  reto  es
mayor cuando  el  paciente  se  encuentra  asintomático,  a  pesar  de  cursar  con  una  trombocitosisPreescolar;
Pediatría;
Recuento  de
plaquetas
descubierta  fortuitamente.
Caso  clínico: nin˜o  de  3  an˜os  de  edad,  asintomático,  cursando  con  trombocitosis  extrema.  Sin
antecedentes  personales  o  familiares  de  importancia.  Se  inició  el  protocolo  de  estudio  descar-
tando errores  de  laboratorio,  procesos  infecciosos,  anemia  hemolítica,  anemia  ferropénica  y
alteraciones  autoinmunes.  La  médula  ósea  obtenida  por  aspiración  reveló  producción  aumen-
tada de  megacariocitos,  sin  alteración  del  resto  de  líneas  celulares.  La  búsqueda  de  alteraciones∗ Corresponding author at: Dr. Balmis 148, Col. Doctores, Del. Cuauhtémoc, Mexico City 06726, Mexico.
E-mail address: rmespinosa1605@hotmail.com (R.M. Espinosa-Elizondo).
http://dx.doi.org/10.1016/j.hgmx.2015.08.003
0185-1063/© 2015 Sociedad Médica del Hospital General de México. Published by Masson Doyma México S.A. All rights reserved.
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genéticas  fue  negativa,  incluyendo  mutación  JAK2.  El  diagnóstico  por  exclusión  fue  trom-
bocitemia  esencial.  Se  prescribió  hidroxiurea  (10  mg/kg)  y  ácido  acetilsalicílico  (5  mg/kg).
Posterior  a  4  semanas  de  tratamiento  se  obtuvo  una  reducción  moderada  de  la  cifra  de  pla-
quetas.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Publicado  por  Masson  Doyma  México
S.A. Todos  los  derechos  reservados.
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hrombocytosis  is  generally  deﬁned  as  a  platelet  count
igher  than  450  ×  109/L.  Mild  thrombocytosis  is  deﬁned
s  a  platelet  count  of  450--700  ×  109/L;  moderate  throm-
ocytosis  is  a  count  of  700--900  ×  109/L;  and  in  severe
hrombocytosis,  platelets  are  higher  than  900  ×  109/L.  A
latelet  count  in  excess  of  1000  ×  109/L  is  considered
xtreme  thrombocytosis.1,2
Thrombocytosis  is  a  common  ﬁnding  on  the  complete
lood  count  of  children,  with  a  reported  prevalence  of
etween  3%  and  15%,  and  a  slight  preponderance  of  boys
s.  girls.  It  is  often  transient,  and  occurs  secondary  to  var-
ous  underlying  medical,  usually  inﬂammatory,  disorders.  It
s  more  common  in  young  children,  either  because  of  the
mmaturity  of  their  innate  and/or  adaptive  immune  systems,
r  because  they  are  more  prone  to  infections.1,2
Essential  thrombocythaemia  (ET)  is  a  chronic  myelo-
roliferative  disorder  characterized  by  megakaryocyte
roliferation.  Although  the  clinical  course  is  benign,  is  it
ssociated  with  serious  thrombosis  and  bleeding,  in  addition
o  an  increased  risk  for  presenting  a  more  serious  haemato-
ogical  malignancy.3--5 Prevalence  is  estimated  at  0.09  cases
er  million  children  between  the  ages  of  0  and  16  years.3,6
n  Mexico,  the  ﬁrst  report  of  a  case  of  infantile  thrombo-
ythaemia  was  published  by  the  Children’s  Hospital  in  1995.3
Over  half  of  all  cases  are  asymptomatic,  and  thrombocy-
osis  is  an  incidental  ﬁnding.  Symptoms  are  nonspeciﬁc,  with
eadache  being  the  most  widely  reported.  There  is  a  high
ncidence  of  serious  thrombosis  (15%),  and  moderate-serious
10%)  and  mild  (15%)  bleeding.  In  2008,  the  World  Health
rganization  issued  revised  diagnostic  criteria  for  myelo-
roliferative  disorder,  establishing  4  major,  and  no  minor,
riteria  for  the  diagnosis  of  ET  (Table  1).4,5
Table  1  Diagnostic  criteria  for  essential  thrombo-
cythaemia  (World  Health  Organization,  20084).
1.  Persistent  platelet  count  ≥  450  ×  109/L.
2. Bone  marrow  histology:  megakaryocyte
proliferation  with  large  and  mature  morphology
with  little  or  no  granulocyte  or  erythroid
proliferation.
3. Not  meeting  WHO  criteria  for  chronic  myeloid
leukaemia,  polycythaemia  vera,  primary
myeloﬁbrosis,  myelodysplastic  syndrome  or  other
myeloid  neoplasm.
4. Demonstration  of  JAK2V617F  or  other  clonal
marker  or  no  evidence  of  reactive  thrombocytosis.
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cThe  JAK2V617F  mutation  occurs  on  the  JAK2  gene
n  chromosome  9  and  triggers  excessive  cell  growth  not
inked  to  growth  factors.4,7 The  mutation  is  present  in
any  patients  with  myelodysplastic  syndromes,  particu-
arly  polycythaemia  vera;  in  ET,  it  is  found  in  23%--57%
f  adults,7 but  according  to  the  review  published  by
ucine  et  al.,  2014,  only  28  mutation  have  been  found  in
hildren.2
Treatment  guidelines  are  controversial  and  involve  either
ydroxyurea  or  anagrelide.8
Hydroxyurea  is  an  antimetabolite  that  selectively  inhibits
ibonucleoside  diphosphate  reductase,  an  enzyme  required
o  convert  ribonucleoside  diphosphates  into  deoxyribonucle-
side  diphosphates,  a  crucial  and  probably  limiting  step  in
NA  synthesis.  Hydroxyurea  is  mainly  used  to  treat  selected
yeloproliferative  disorders.
Anagrelide  is  an  imidazoquinazoline  that  inhibits
egakaryocyte  maturation  and  reduces  elevated  platelet
ounts.8
In  this  study,  we  report  the  case  of  an  uncommon  clinical
resentation  in  a paediatric  patient.
ase report
he  patient  was  a  boy  aged  3  years  (born  in  2011),  a  res-
dent  of  Mexico  City,  with  no  family  history  of  note.  The
ather  and  mother  were  both  healthy,  aged  38  and  34,
espectively.
The  patient  lives  in  an  urban  dwelling,  far  from  industrial
reas,  power  lines  and  landﬁll  sites.  He  denies  contact  with
yelotoxic  substances,  such  as  pesticides,  benzene,  ionizing
adiation,  or  heavy  metals.
He  is  the  mother’s  third  child  following  an  uneventful
regnancy,  weighing  3.150  g  at  birth  and  measuring  49  cm.
edical  history
omatic  and  functional  development.  No  changes  relevant
o  the  current  complaint.  Immunizations  up  to  date.
urrent  complaintsymptomatic  patient  referred  to  Paediatric  Haematol-
gy  following  extreme  thrombocytosis  of  1,492,000  ×  109/L
ound  during  blood  tests  performed  on  25  February  2014.
he  blood  count  was  part  of  the  preoperative  workup  for
ircumcision  and  right  side  orchidopexy.  The  protocol  for
hildhood  thrombocytosis,  shown  in  Fig.  1, is  started.
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CFigure  1  Diagnostic  algorithm  to  conﬁ
Physical  examination
Well  developed  male  patient,  conscious  and  oriented,
active,  reactive,  with  no  pallor,  pupils  equal  and  reactive  to
light,  oral  mucosa  moist.  No  mucosal  lesions,  no  evidence  of
adenopathy,  lung  ﬁelds  are  clear  and  well-ventilated,  heart
has  regular  rate  and  rhythm,  no  murmurs,  abdomen  soft,
depressible  and  non-tender,  no  hepatosplenomegaly,  normal
peristaltic  sounds,  no  masses,  well-developed  genitals,  full
T
t
ﬁ
cspicion  of  essential  thrombocythaemia.
ange  of  motion  in  extremities,  with  no  oedema  or  evidence
f  venous  or  arterial  problems.
linical  coursehe  boy  was  seen  again  in  April  with  the  results  of  the
est  (Fig.  1) performed  to  rule  out  other  diseases.  The
ndings  of  a  new  whole  blood  count  showed  a  platelet
ount  of  971,000.  The  interview  and  physical  examination
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Leukocytes
(6 - 15 x10^3/ml) 10.713.611.911.37.57.97.518.3
Neutrophils
(6 - 10 x10^3/ml) 5.67.6266.7543.634.4
Lymphocytes
(2 - 8  x10^3/ml) 3.62.723.76.71.32.82.682.9
Hemoglobin
(12-15  g/dL) 11.812.512.412.912.912.812.212.2
Hematocrit
(36 - 45 %) 35.836.537.538.33937.735.537.2
Platelets 2434245431538605578849711,429
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Figure  2  Changes  in  blood  chemistry  para
ere  both  compatible  with  viral  inﬂuenza  associated  with
hrombocytosis,  and  the  patient  was  given  symptomatic
reatment.
At  the  following  appointment,  on  September  3,  2014,
he  platelet  count  was  3,153,000,  and  the  patient  was
otally  asymptomatic.  Therefore,  after  ruling  out  other
nderlying  conditions  that  could  be  causing  the  throm-
ocytosis,  we  suspected  essential  thrombocythaemia,  and
rdered  bone  marrow  aspiration  and  speciﬁc  molecular
esting.  The  ﬁndings  of  these  tests  met  the  diagnostic
riteria  for  ET,  and  the  diagnosis  was  therefore  conﬁrmed
Table  1).
aboratory  and  molecular  biology  studies
ig.  2  shows  the  changes  in  blood  chemistry.
Iron  metabolism  parameters  in  the  normal  range.  Sero-
ogy  negative  for  infection.
Vitamin  B12  quantiﬁcation:  520  pg/ml  (reference  range:
00--900  pg/ml)  and  functional  antithrombin  III  118%  (refer-
nce  range:  80--120%).
Molecular  biology  studies:  Normal  karyotype  (46  XY).
CR/ABL1  Negative  (19/09/2014).  JAKV617F  not  mutated
23/09/2014).
linical  and  invasive  studies
n  abdominal  ultrasound  performed  in  September  2014  was
nremarkable,  with  a  normal  spleen  (9  cm  greatest  diame-
er).On  September  10,  2014,  bone  marrow  aspiration  was
erformed,  showing  normocellular  bone  marrow  with  abun-
ant,  greatly  enlarged  megakaryocytes  forming  platelet
lumps  with  abundant  cytoplasm  and  irregular,  hyperlob-
lated  nuclei;  architecture  is  otherwise  preserved,  with  a
light  increase  in  eosinophils  (Fig.  3).
s
i
a
g
trs.  Reference  ranges  and  units  in  brackets.
herapeutic  management
he  patient  was  started  on  10  mg/kg  hydroxyurea  and
 mg/kg  acetylsalicylic  acid  on  September  4;  4-week  follow-
p  showed  a  moderate  reduction  in  platelet  count.
iscussion
n  paediatric  patients,  an  incidental  ﬁnding  of  thrombocy-
osis  should  be  conﬁrmed  with  an  additional  blood  count,  as
ome  clinical  situations  can  cause  a  false  high  platelet  count
mixed  cryoglobulinaemia  or  lysis).  The  primary  aim  should
e  to  stabilize  the  patient,  and  then  follow  the  algorithm
hown  in  Fig.  1  to  conﬁrm  a  diagnosis  of  secondary  or  clonal
hrombocytosis.9 These  studies  are  performed  in  sequence
o  rule  out  the  main  underlying  causes  of  secondary  throm-
ocytosis.  They  include  tests  for  infection,  iron  deﬁciency
naemia,  haemolytic  anaemia,  and  autoimmune  disease.6,10
lthough  platelet  clumping  tests  were  not  performed  in  this
ase,  they  can  give  valuable  insight  into  platelet  function.
rimarily,  they  provide  a  clearer  picture  of  the  risk  of  pre-
enting  thrombotic  complications  from  platelet  activation.
n  addition,  reports  have  shown  that  in  patients  with  very
igh  platelet  levels,  the  likelihood  of  haemorrhage  paradox-
cally  increases  as  a  result  of  the  increased  proteolysis  of
arge  vWF  multimers.7,11
It  is  important  to  evaluate  the  family  history  of  thrombo-
ytosis,  as  this  can  suggest  hereditary  thrombocytosis.  Some
tudies  have  reported  families  with  thrombocytosis-causing
utation  isolated  in  the  thrombocytopenia  gene,  the  TPO
MPL  receptor  gene  (MPL),  and  more  recently,  JAK2.
The  ﬁnal  step  involves  bone  marrow  aspiration,  which
hows  the  presence  of  megakaryocyte  proliferation,  with  an
ncrease  in  the  number  of  mature  enlarged  megakaryocytes
nd  no  signiﬁcant  increase  or  shift  to  the  left  of  neutrophil
ranulopoiesis  or  of  erythropoiesis.12
The  presence  of  the  BCR-ABL  fusion  gene  rules  out  essen-
ial  thrombocythaemia.  Samples  must  be  tested  for  the
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Figure  3  Photomicrograph  of  bone  marrow  aspirate  obtained  from  the  sternum,  magniﬁed  400×  (A)  and  1800×  (B).  It  shows  normo-
cellular bone  marrow  with  abundant,  greatly  enlarged  megakaryocytes  with  abundant  cytoplasm  and  irregular  nuclei.  Architecture
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Ris otherwise  preserved,  with  a  slight  increase  in  eosinophils.
JAK2V617F  mutation  (positive  in  40%--50%  of  all  cases)  or
MPLW5151K/L  (1%  of  all  cases).13,14 A  ﬁnding  of  JAK2V617F
mutation  in  addition  to  the  foregoing  bone  marrow  ﬁndings
contributes  to  the  diagnosis  of  myeloproliferative  neoplasm.
The  prevalence  of  essential  thrombocythaemia  is  around
60  times  greater  in  adults  than  in  children.  The  JAK2V617F
mutation  is  also  less  common  in  children,  making  pathogen-
esis  and  diagnostic  techniques  in  children  a  considerable
challenge.1 In  the  case  presented  here,  the  patient  met
all  the  diagnostic  criteria  for  ET  (Table  1),  because  despite
the  absence  of  the  JAK2V617F  mutation,  any  other  origin
of  thrombocytosis  was  ruled  out  following  the  recommen-
dations  of  the  latest  WHO  guidelines.  It  is  also  important  to
bear  in  mind  that  although  JAK2V617F  is  the  most  common
mutation,  another  mutation  occurring  within  exon  12  of  the
JAK2  gene  has  a  similar  effect  as  JAK2V617F.  The  mutation,
however,  has  primarily  been  reported  in  other  myeloproli-
ferative  neoplasms,  such  as  polycythaemia  vera.15
There  are  2  main  therapeutic  options  in  the  manage-
ment  of  patients  with  ET:  (A)  Antiplatelets  (acetylsalicylic
acid),  usually  used  in  a  conservative  ‘‘wait  and  see’’  con-
text;  (B)  Cytoreductive  therapy.  The  latter  is  reserved  for
cases  of  severe  ET,  in  other  words,  in  patients  aged  60
years  or  older  with  other  comorbidities  or  thrombotic  and/or
bleeding  complications,  or  when  the  platelet  count  exceeds
1500  ×  109/L,  as  was  the  case  with  our  patient.2,5
Although  some  cytoreductive  therapies  in  children  have
been  reported,  the  lack  of  evidence  has  prevented  any
clear  consensus  on  the  correct  approach.  This  is  why  the
main  sources  for  such  treatment  consist  of  case  reviews
reporting  the  successful  use  of  hydroxyurea,  with  anagre-
lide  and  interferon  being  considered  second  line  treatment
in  high  risk  patients  that  either  do  not  tolerate  or  do  not
respond  to  hydroxyurea.  Some  authors  have  recently  pointed
to  interferon  alpha  as  the  treatment  of  choice,  based  on
its  excellent  safety  proﬁle  even  in  pregnant  women,  and
because  it  does  not  increase  the  already  considerable  risk
of  leukaemia.16,17 Although  Giona  et  al.,  in  a  retrospec-
tive  analysis  of  the  3  available  cytoreductive  drugs,  chose
interferon  over  other  remedies,  they  recommend  evaluating
therapy  on  a  case-by-case  basis,  and  ultimately  consider  all
3  agents  to  be  equally  effective.5,17 Experience  in  the  use
of  anagrelide  is  limited,  and  it  is  relegated  to  second  lineherapy.16,18 On  this  basis,  and  in  consideration  of  the  high
ost  of  other  options,  we  chose  to  treat  our  patient  with
ydroxyurea.  This  therapy  has  the  added  advantage  of  oral
dministration,  in  contrast  to  interferon  alpha,  which  must
e  administered  by  trained  staff.
onclusion
ssential  thrombocythaemia  is  an  uncommon  disorder  in
hildren.  For  diagnostic  purposes,  it  is  of  vital  importance  to
ifferentiate  between  essential  thrombocythaemia  and  sec-
ndary  thrombocytosis;  a  negative  JAK2  mutation  test  does
ot  necessarily  rule  out  the  diagnosis,  and  treatment  should
e  started  in  symptomatic  patients,  or  in  those  at  high  risk
or  complications.
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